Clinical Trials on Parainfluenza

Total 22 results

ModernaTX, Inc.

Active, not recruiting

Safety and Immunogenicity of mRNA-1653, a Combined Human Metapneumovirus (hMPV) and Parainfluenza Virus Type 3 (PIV3) Vaccine, in Healthy Adults, and Children 12 to 59 Months of Age With Serologic Evidence of Prior Exposure

Human Metapneumovirus and Human Parainfluenza Infection

United States
National Institute of Allergy and Infectious Diseases...

Completed

Safety of a Live Attenuated Human Parainfluenza Virus Type 2 (HPIV2) Vaccine for Adults, Children, and Infants

Human Parainfluenza Virus 2

United States
MedImmune LLC

Completed

A Study to Evaluate the Safety, Tolerability, Immunogenicity and Vaccine-like Viral Shedding of MEDI-534, Against Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3), in Healthy 6 to <24 Month-old Children and in 2 Month-old Infants

Healthy

United States, Australia, Spain, Germany, Canada, Finland, South Africa, Brazil, Israel
National Institute of Allergy and Infectious Diseases...

Withdrawn

DAS181 in Patients With Parainfluenza

Parainfluenza Infection
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Safety and Immunogenicity of a Human Parainfluenza Type 3 (HPIV3) Virus Vaccine in Infants and Children

Parainfluenza Virus 3, Human

United States, Puerto Rico
MedImmune LLC

Completed

Study to Evaluate the Safety of MEDI-534 Vaccine Against Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3) in Healthy Children

Healthy

United States
ModernaTX, Inc.

Completed

Safety, Reactogenicity, and Immunogenicity of mRNA-1653 in Healthy Adults

Human Metapneumovirus and Human Parainfluenza Infection

United States
MedImmune LLC

Completed

Study to Evaluate MEDI-534 in Healthy Adults

Respiratory Syncytial Virus Infections | Parainfluenza Infections

United States
Imperial College London
Sense Biodetection Limited

Unknown

Evaluation of a Single Use Point of Care Device for the Diagnosis of Respiratory Pathogens (SIMPLIFI)

Enterovirus Infections | Respiratory Syncytial Virus Infections | Human Influenza | Rhinoviral Infections | Metapneumovirus Infection | Parainfluenzae Viral Infections

United Kingdom
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Safety of and Immune Response to a Human Parainfluenza Virus Type 3 Ebola Virus Vaccine (HPIV3-EbovZ GP) in Healthy Adults

Hemorrhagic Fever, Ebola

United States
National Institute of Allergy and Infectious Diseases...

Suspended

Evaluating the Live-Attenuated Human Parainfluenza Virus Type 3 Vectored Vaccine Candidate Expressing Ebolavirus Zaire Glycoprotein as the Sole Envelope Glycoprotein

Ebola Virus Disease

United States
Ansun Biopharma, Inc.

Completed

An Open Label Study to Examine the Effects of DAS181 Administered by Dry Powder Inhaler (DPI) or Nebulized Formulation in Immunocompromised Subjects With Parainfluenza (PIV) Infection (PIV)

Parainfluenza

United States
MedImmune LLC

Completed

Safety and Tolerability Study to Evaluate MEDI-534 in Children 6 to < 24 Months of Age (CP149)

Respiratory Syncytial Virus Infections | Respiratory Viral Infections | Parainfluenza Virus 3, Human

United States
National Institute of Allergy and Infectious Diseases...
Johns Hopkins Bloomberg School of Public Health

Completed

Safety of and Immune Response to Recombinant Live-Attenuated Parainfluenza Type 1 Virus Vaccine

Virus Diseases | Parainfluenza

United States
Ansun Biopharma, Inc.

Completed

A Phase II, Randomized, Double-blind, Placebo-controlled Study to Examine the Effects of DAS181 in Immunocompromised Subjects With Lower Respiratory Tract Parainfluenza Infection on Supplemental Oxygen (DAS181-2-05)

Parainfluenza

United States
MedImmune LLC

Terminated

A Phase 1/2A Study to Evaluate the Safety, Immunogenicity, and Shedding of MEDI-560 in Infants 1 to < 12 Months of Age

Healthy

United States
QIAGEN Gaithersburg, Inc

Completed

Collection and Testing of Respiratory Samples

Respiratory Syncytial Virus Infections | Influenza A | Rhinovirus | Influenza B | QIAGEN ResPlex II Advanced Panel | Infection Due to Human Parainfluenza Virus 1 | Parainfluenza Type 2 | Parainfluenza Type 3 | Parainfluenza Type 4 | Human Metapneumovirus A/B | Coxsackie Virus/Echovirus | Adenovirus Types B/C/E | Coronavirus Subtypes 229E and other conditions

United States
AlloVir

Terminated

Study of ALVR106 in Patients With Respiratory Viral Infections After Hematopoietic Cell and Solid Organ Transplant

Influenza Infection | Respiratory Tract Viral Infections | Human Metapneumovirus (hMPV) Infection | Parainfluenza (PIV) Infection | Respiratory Syncytial Viral (RSV) Infection

United States
St. Jude Children's Research Hospital

Suspended

A Study to Assess the Safety of Live Intranasal Sendai Virus Vaccine in Children and Toddlers

Parainfluenza | Respiratory Viral Infections

United States
Assistance Publique - Hôpitaux de Paris

Unknown

Signature of the Host Response to a Respiratory Viral Infection, in the Prediction of Bronchiolitis Obliterans (ALLOPIV)

Acute Respiratory Infection | Allogeneic Hematopoietic Stem Cell Recipients | Parainfluenza Virus (PIV)

France
University College, London
Public Health England

Completed

Specific Respiratory Infections as Triggers of Acute Medical Events

Cardiovascular Diseases | Influenza, Human | Respiratory Syncytial Virus Infections | Adenovirus | Rhinovirus | Parainfluenza | Human Metapneumovirus Pneumonia

United Kingdom
Ansun Biopharma, Inc.

Recruiting

Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study

COVID-19 | Lower Respiratory Tract Infection | Immunocompromised | Parainfluenza

United States, Australia, China, Denmark, France, Hong Kong, Korea, Republic of, Taiwan

Clinical Trials on Parainfluenza

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Australia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations